M Michael Chuong, M.D.

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use …

Z Zhang Zhenfeng, MD, PhD

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells …

A Alexandre Brind'Amour

Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX

This is a prospective, pilot study from a single center. Patients will be evaluated and operated on by one of five surgeons with a subspeciality in hepato-biliary and pancreatic surgery. After thorough, standard of care assessment for both pancreatic primary and liver metastases resectability with blood tumor markers (CEA, CA …

S Saleh K Saleh, MD

Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)

This study investigates the safety and efficacy of injecting N-butyl-2-cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during pancreaticoduodenectomy (PD) to enhance the security of the pancreaticojejunostomy (PJ) anastomosis and reduce postoperative pancreatic fistula (POPF) rates.

S Saleh K Saleh, MD

Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate

This randomized controlled trial investigates the safety and efficacy of injecting N-butyl-2- cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during pancreaticoduodenectomy (PD) to enhance the security of the pancreaticojejunostomy (PJ) anastomosis and reduce postoperative pancreatic fistula (POPF) rates.

X Xia Huanyu MD

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas

J Jean-Pierre BLEUSE, MD

Prospective Monocentric Clinical-biological Database

Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this type of tumor have been steadily increasing for two decades. In the absence of therapeutic advances, PA …

C Chunmei Bai, M.D.

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are prognostic value of baseline MRD; the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood …

M Medical College of Wisconsin Cancer Center Clinical Trials Office

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.

M Medical College of Wisconsin Cancer Center Clinical Trials Office

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.